Overview
Ibogaine is a psychoactive indole alkaloid from the root bark of Tabernanthe iboga. Alongside its reported effects on opioid withdrawal, people who take it commonly describe a prolonged, dreamlike autobiographical review followed by a period of reflection they characterise in moral or spiritual language. "Spiritual reset" is the popular shorthand for that second phase[12][13].
The term has no agreed definition and no validated measure specific to ibogaine. Academic work on ibogaine has documented the treatment subculture and the meaning participants attach to their sessions[5][6], while the quantitative study of comparable experiences comes mostly from psilocybin research[1][3]. Related pages: ego dissolution, Bwiti and ibogaine effects on the brain.
What people describe
Accounts collected by providers and community sites converge on a recognisable sequence: an acute visionary phase lasting several hours, a long introspective phase in which memories and relationships are reviewed with unusual emotional distance, and a low-energy recovery period in which people report re-evaluated priorities and reduced compulsion[12][13][14]. Ethnographic work on the ibogaine subculture records the same framing — treatment understood as a moral turning point rather than only a pharmacological detoxification[5]. These are self-reports, not measured outcomes.
Mystical-type experience research
The best-characterised research on experiences of this kind used psilocybin under controlled conditions. A double-blind study reported that psilocybin can occasion mystical-type experiences with substantial and sustained personal meaning and spiritual significance[1], and a follow-up analysis found that the intensity of the mystical-type experience statistically mediated the personal meaning and spiritual significance participants attributed to the session fourteen months later[2]. The instrument used in this work, the revised Mystical Experience Questionnaire, was subsequently validated in experimental psilocybin sessions[3].
This literature matters for two reasons: it shows that experiences described in spiritual terms can be measured reproducibly, and it shows that their intensity can predict later reported meaning. It does not transfer automatically to ibogaine, whose pharmacology, duration and risk profile differ substantially.
Ego dissolution and the default mode network
"Ego dissolution" — a temporary weakening of the felt boundary between self and world — is the component of these experiences most often connected to a sense of reset. A systematic review of neuroimaging studies found that classic psychedelics consistently modulate the default mode network, the set of regions associated with self-referential thought, and that these changes are frequently reported alongside subjective self-boundary effects[4]. Comparable imaging work specific to ibogaine in humans is scarce, so the mechanistic link for ibogaine remains inferred rather than demonstrated. Community and provider material nevertheless uses the same vocabulary[13][14]. See also noribogaine, the long-lived metabolite implicated in the extended after-phase.
Bwiti and the cultural origin of the framing
Iboga is a sacrament in Bwiti, a set of religious traditions in Gabon and neighbouring countries, where high-dose ingestion is central to initiation and is understood as an encounter with ancestors rather than as medicine[15][16]. Western "spiritual reset" language borrows loosely from that tradition while removing its ritual structure, community and duration of preparation — a shift the academic literature on the ibogaine subculture documents explicitly[5]. The Bwiti page covers the tradition in detail.
Relation to treatment outcomes
Observational studies of ibogaine for substance dependence report short-term reductions in withdrawal and craving and, for some participants, sustained reductions in use over twelve months[7]. A retrospective study of drug-dependent patients treated with ibogaine likewise reported extended abstinence periods in a subset, with the authors noting the absence of controls[6]. In trauma-related conditions, a 2024 open-label study of magnesium–ibogaine in veterans with traumatic brain injury reported improvements in functioning and psychiatric symptom scores at one month, again without a control group[10]. Whether the subjective quality of the experience drives those outcomes has not been tested in ibogaine research.
Limits of the evidence
- No randomised controlled trial of ibogaine has reported spiritual or mystical-experience outcomes.
- The mediation finding linking experience intensity to later meaning comes from psilocybin studies, not ibogaine[2].
- Ibogaine outcome studies are open-label or retrospective, with self-selected participants and high loss to follow-up[6][7].
- Difficult, frightening or destabilising sessions also occur; reviews of adverse events describe neurological and psychiatric as well as cardiac effects[9].
- A single session is not a substitute for continuing care; reviews of the field emphasise relapse risk without aftercare[11].
Risks and cardiac safety
Ibogaine blocks the hERG potassium channel and prolongs the QT interval, which can cause torsades de pointes and cardiac arrest[8]. A systematic review of adverse events in humans records deaths as well as non-fatal cardiac, neurological and gastrointestinal events, concentrated in unmonitored settings[9]. Standard precautions in supervised settings include a baseline electrocardiogram, magnesium and potassium correction, liver function testing, medication review and continuous cardiac monitoring[10]. Seeking a spiritual experience does not change that risk profil